Everest Medicines Limited, incorporated in the Cayman Islands and listed under Stock Code 1952, has announced the completion of a placing of existing shares and a top-up subscription of new shares under a general mandate. The company successfully placed an aggregate of 22,561,000 sale shares through placement agents, on a best effort basis, to not less than six placees, at a purchase price of HK$69.70 per sale share. This strategic move is part of the company's efforts to optimize its capital structure and support its ongoing business initiatives. Everest Medicines' Board, led by Chairman and Executive Director Wei Fu, expressed satisfaction with the successful completion of the transaction.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。